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FOCUS: TOP-DOWN MASS SPECTROMETRY
EDITORIAL
Focus in Honor of Dr. Neil Kelleher, Recipient
of the 2009 Biemann MedalThis special focus issue of the Journal of the Amer-ican Society for Mass Spectrometry celebrates theaccomplishments of the 2009 Biemann Medalist,
Professor Neil Kelleher. The focus contains a total of
nine papers devoted to top-down mass spectrometry of
proteins and oligonucleotides. The development of top-
down mass spectrometry and top-down proteomics is
largely due to Neil Kelleher, who has vigorously pro-
moted this technology, starting as a graduate student
and continuing today. Unlike the bottom-up approach
that starts with protein fragments, top-down proteom-
ics preserves information concerning protein isoforms
and the interplay between post-translational modifica-
tions by isolating and fragmenting whole proteins in the
gas phase. Neil’s group has applied top-down analysis to
a number of important biological systems, including the
protein component of human chromatin and the post-
translational dynamics of histone H4 through the cell
cycle. His lab over the past decade at the University of
Illinois in Urbana-Champaign (and at Northwestern Uni-
versity in mid-2010), has three main sub-groups working
in the area of top down proteomics, natural products
biosynthesis/discovery, and chromatin biology. The core
of the group is built around expertise in technology
development for complex mixture analysis using Fourier-
transform mass spectrometry.
Over the past few months, I had the opportunity to
discuss with Neil his background and motivation for
his research:
Joe Loo: Hi Neil. Congratulations on your selection
as the 2009 Biemann Medalist for your contributions
towards the development of the top-down approach. I
think the readers would be interested in learning about
your personal and scientific background and the moti-
vation for your research. Let’s start with your formal
education. You and I share the same Ph.D. mentor,
Professor Fred McLafferty, at Cornell University. How
did you decide to attend Cornell?
Neil Kelleher: Thanks, Joe. That’s a funny story of
fate, perhaps. I was on a scholarship in Konstanz,
Germany, doing moderate-to-bad synthetic chemistry
when I met Fred after his spectacular seminar on
combining Electrospray with FTMS. The year was 1992.
The next thing I knew, I was headed to Ithaca, NY!
J.L.: Didn’t you know that Ithaca is cold, snowy, and
gray? I realize that Fred is an energetic and engaging
person, but how did he convince you to return to the
U.S. and work on a mass spectrometry project?
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faze me. Fred is a persuasive force and I signed on for
just a lovely summer, at first.
J.L.: What type of research did you expect to engage
in when you joined Fred’s group?
N.K.: Since I was synthesizing oligonucleotides in
Germany, and Fred wanted to sequence DNA with
mass spectrometry, it was the obvious place to begin.
Life with negative ions was short-lived, and I quickly
switched to proteins, in part because of a strong interest
in enzyme biochemistry.
J.L.: Oh, Hi Fred (McLafferty)! I didn’t see you
standing there. So, what was Neil really like as a
graduate student? I remembered visiting you around
ass Spectrometry.
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impression of him was that he was very enthusiastic
and full of energy (almost “hyper”). I also remembered
him bouncing a basketball all the way down to a
restaurant in Collegetown while we were walking to
lunch.
Fred McLafferty: First, Neil was an “8-hour per day”
man. He really did that for my research, although later
Professor Tadhg Begley claimed that Neil was 8-h per
day for him also. But then Professor Pete Wolczanski
confessed that a qualification shortage forced him to use
Neil every Friday pm for “golf research.” Neil was also
our greatest PR man (e.g., after my 1992 Konstanz
seminar described above as “spectacular,” there was
dead silence—no questions—until finally this short guy
in the top row asked something like “Is this the best MS
research of the past decade?”).
J.L.: Neil, how did the term “top-down” originate? I
think the first time I read about “top-down” sequencing
or the “top-down” approach was in your 1999 paper in
the Journal of the American Chemical Society.
N.K.: It was in some of Fred’s grant proposals and
also in a letter from Fred to then-recruit Mike Senko
dated November, 1990—long before I got involved. As
high-throughput bottom-up took hold during the 1990s,
“top-down” proteomics was a pretty clear next step as
I sought gainful employment in 1999.
J.L.: Fred, is Neil’s account of the origin of the
“top-down” term accurate? I wasn’t sure if “top-down”
was used before your 1999 JACS paper. If one searches
“top-down” on the Internet, the top hits describe a style
of computer programming, an investment strategy, and
a management and decision-making processes. If you
were the first to coin “top down,” then you should have
trademarked it. It would have been worth a fortune.
F.M.: I haven’t looked for written evidence of “top-
down” use before 1990. Before electrospray, however, MS
structure characterization always started with the molec-
ular ion—how could the protein digesters not understand
this? As a confession, the term “bottom-up” had connota-
tions that expressed my opinion of their approach, which
necessitated the use of “top-down” for ours.
J.L.: Thanks, Fred, for stopping by. Neil, we
shouldn’t neglect mentioning your other mentor at
Cornell whom Fred just brought up, Professor Tadhg
Begley (who recently moved to Texas A & M Univer-
sity). How did your interaction with Professor Begley
shape the type of research that you pursue now?
N.K.: The simple answer is “a lot.” The long answer
is that it sent me down the road of interdisciplinary
research, which has expanded significantly in the
“omic” era. More specifically, it led me into enzymol-
ogy, which in turn bounced me to Chris Walsh (Har-
vard Medical) and ultimately explains both my hyper-
active nature and the fact that about one-third of my
group works in the area of natural products biosynthe-
sis/discovery from soil and marine bacteria.
J.L.: What was your thought process in choosing
Professor Walsh’s lab for a post-doc? At this point inyour career, had you already decided that you were
headed to academia for your long-term future?
N.K.: It was more of a gut-level leap, somewhat
unencumbered by the thought process. The notion was
to gain more depth in enzymology to position myself
better for top academic posts. I applied to Perry Frey at
Wisconsin, Chris’s lab, and a few other top mass
spectrometry (proteomics) labs as well.
J.L.: What did you take away (not literally, of course)
from each of your formal mentors (McLafferty, Begley,
Walsh) that helped you in how you do scientific research
currently (e.g., choosing a research problem, how you
manage your group, how to write manuscripts, etc.)?
N.K.: Wow – everything!?! Fred taught me how to
write, Tadhg taught me how to think in that classical,
hypothesis-driven mode, and Chris pushed me to ma-
ture and think strategically. There’s so much more
there—just leading by example, advocacy over the
years, and helping nudge me in the right direction. Soft
nudges from people you revere have powerful out-
comes. I now seek avenues to pay this stuff “forward.”
J.L.: Since you started your academic career at Illi-
nois, you and your group have been focused on im-
proving the overall methodology of the top-down mass
spectrometry strategy. I’ve been impressed that your
group has expended a lot of effort in all phases of the
platform, including sample preparation, instrumenta-
tion, informatics, and biological applications. In your
view, which of these four aspects is the most mature
and nearly “ready to go” if one considers what top-
down MS will look like 5 to 10 years from now?
N.K.: My Biemann Award lecture had this basic
structure to it, and I projected then that the software
aspects were most refined and “ready-to-rumble.” Soft-
ware will always be improving, but conceptually and in
a few labs, it’s already there.
J.L.: Which of these areas needs the most improve-
ment for top-down MS to be nearly as routine and
widespread as the bottom-up methodology?
N.K.: That one is absolutely clear ¡ sample prepa-
ration, especially the protein fractionation challenges
above 50 kDa. Even if instruments continue on a steady
course of improving by a small factor each year, they
will not be limiting until the “front-end” problem for
top-down has been wrestled to the ground.
J.L.: In hindsight and thinking back when you first
started at Illinois, which of the four areas surprised you
regarding how difficult it would be to make significant
improvements?
N.K.: The separations. I’m not a chromatographer by
training, but still—it has taken some remarkable talent
in the lab to get this under control. It’s coming, but after
a decade of trying, we are just now seeing something
like a platform emerging that non-aficionados can
adopt.
J.L.: Is there a particular technological area that I
neglected to mention that needs to be addressed before
top-down will be possible on a large scale?
iiiJ Am Soc Mass Spectrom 2010, 21, i–iii LOON.K.: Yes and No. The “no” response describes the
reality that a well-honed technology results from the
contributions of many constituencies putting skin into
the game—academic, corporate, and government. Peo-
ple are just starting to turn their attention (and re-
sources) to the top-down horizon. So there will be
dozens of labs and improvements to come over the next
(half-) decade, and an engineering ethos will take
hold—slowly. What could warp us ahead is the unpre-
dictable—like a technology such as Supercharging in
ESI. I know people like Evan Williams, you, and Jenny
Brodbelt are working on this, so I have one message¡
“Hurry up”!
J.L.: Could you comment on how you envision
getting top-down MS to the “masses”? What I mean by
my question is that having high resolving power (and
mass accuracy, of course) is a prerequisite for top down
of large proteins. Currently, FT-ICR analyzers with
large superconducting magnets are the primary plat-
forms for top-down. I suppose Orbitrap performance
for large proteins will improve in the future. However,
both options are fairly expensive for most labs. Do you
think that this situation will limit the spread of top-
down MS, or do you believe that top-down will be
concentrated in specialized labs that have accumulated
the necessary expertise and hardware?
N.K.: There are clearly less expensive hardware
options, such as benchtop FTMS (Orbitrap) systems and
TOFs. ITMS often suffices for intact masses, so long as
fragment ions are measured at high accuracy for reli-
able database searching. So I see a clear path ahead for
development of both ‘inexpensive’ and ‘expensive’ fla-
vors of top-down, but the main issue is people’s mind-
set. Starting in expert labs, one can see evidence for
propagation outward now (e.g., BioPharma), but the
status of the bottom-up/top-down dichotomy a decade
from now is difficult to predict.
J.L.: How do you feel about the “middle-down”
approach in which larger proteins are cleaved into
relatively large pieces before MS/MS analysis? Are
there unique roles and/or application for the middle
down strategy?
N.K.: Driven by increased use of e–1-based MS/MS,
and clear successes in histone MS, this area that Cathe-
rine Fenselau called “middle molecule” MS some 20
years ago is small, but growing. My good friend and
colleague Mike Senko calls this “Goldilocks” proteom-
ics, after the famous children’s story from the UK. So if
intact proteins are too big right now, and little tryptic
peptides are too small for maximal protein coverage,
perhaps mid-sized peptides are just the ticket to getsome “top down-like” advantages reaching more peo-
ple and serve as a stepping-stone on the way toward
more widespread and routine top-down MS.
J.L.: You’ve been really active in applying top down
mass spectrometry to address the biosynthesis and
discovery of polyketides and non-ribosomally pro-
duced peptides. I assume this originated from your
work with the Walsh lab. What capabilities of the
top-down approach make it especially suitable for this
research area?
N.K.: The practical advantage of keeping all parts of
the protein together. These enzymes all share a covalent
but labile cofactor that carries all the biosynthetic inter-
mediates. We tickle them with vibrational energy and
much like the ion chemistry of phospho-peptides, this
cofactor pops right off and reduces even 200 kDa
proteins down to 1 ions below 1000 m/z. A half-dozen
or so enzymologists have used this trick at the protein
level, and after hunting down the right peptide, with
proteolysis as well.
J.L.: Are there applications that you’re dying to get
into, but you didn’t feel that the current capabilities of
top-down were suitable yet?
N.K.: Systems biology. Top-down has involved
mostly technology development. However, levels of
throughput and proteome coverage are now rising to
the point where we can actively dive in, swim with the
bigger fish, and make some waves.
J.L.: You’ve had a number of students graduate with
a degree since you’ve been in academia. What kind of
advice are you giving them as they begin their indepen-
dent scientific careers?
N.K.: In short, to know more than mass spec and to
seek leadership positions. Students are expected to be
well-grounded in our core area of expertise, but also
have great depth in at least one other area (e.g., enzy-
mology, computer science, chromatography, or a tar-
geted area of cell biology). Of our 20 Ph.D.s— they
have fanned out and have done quite well indeed. I get
a fair amount of targeted e-mail and phone traffic
seeking more talent for academic, corporate, and hybrid
positions. We had a big celebration dinner at ASMS in
Philadelphia. It was amazing to see how great people
were doing and how fast time passes.
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